Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Invalda INVL M&A Activity 2011

Aug 19, 2011

2247_rns_2011-08-19_e6ee1b1f-c21c-47cd-b03d-75cda15569fe.html

M&A Activity

Open in viewer

Opens in your device viewer

Invalda AB sold 26.5% shareholdings in AB Sanitas for 83 mln. EUR

Invalda AB sold 26.5% shareholdings in AB Sanitas for 83 mln. EUR

Vilnius, Lithuania, 2011-08-19 11:34 CEST (GLOBE NEWSWIRE) -- Invalda AB and
other Sanitas AB shareholders, all together controlling 87,2% shares, on 19
August 2011, have finished the sale of this shareholding in Sanitas AB to
Valeant Pharmaceuticals International, Inc.

According to the agreement signed on 23 May 2011, Invalda AB has sold 26.5%
shareholdings in AB Sanitas, in exchange of 83 mln. EUR (286.7 mln. LTL) or
10.06 EUR (34.7 LTL) for one share.

Taking into account share price adjustment mechanism set out in the agreement
signed on 24 October 2008, (regarding sale of 20.3 % of the share capital of
Sanitas AB) total proceedings of Invalda from Sanitas shares will amount to
91.4 mln. EUR (315.7 mln. LTL) (based on the EUR/USD exchange rate 1.43). This
amount may change depending on USD rate.

The preliminary net gain in the standalone financial statements of Invalda AB
is approximately 59.7 mln. EUR (206.1 mln. LTL) and consolidated financial
statements - 54.9 mln. EUR (189,5 mln. LTL).

Invalda AB will use proceeds from the transaction to cover practically all
financial obligations to banks and group companies, allocating for this 106.6
mln. LTL (30.87 mln. EUR). The company is also actively looking for new
investment projects.

A person authorised to provide additional information:
Darius Sulnis, president, phone number: +370 5 2734876

     Kristina Gudauskaite
     Assistant to president
     Tel. + 370 5 2752776